Year: 2020

Reported production sales volume of 2.8 million barrels of oil equivalent (“MMBoe”) for the third quarter of 2020, exceeding the high end of guidance by 9%         Oil production sales volume of 1.5 million barrels of oil (“MMBbls”) for the third quarter of 2020; 53% of total equivalent production sales volume Cash flow positive for the quarter with net bank debt1 reduced 34% compared to the end of the second quarter Reported a GAAP net loss of $16 million, or $3.72 per diluted share with adjusted net earnings2 of $17 million, or $4.01 per diluted share and EBITDAX2 of $64 million Excluding the impact of reverse stock split3 adjusted net earnings per diluted share were $0.08 Recently announced a definitive agreement to merge with Bonanza Creek in a strategic combination that creates a large-scale rural DJ Basin...

jf. vedhæftede dokument.Vedhæftet filSelskabsmeddelelse nr 16-2020

– Raised $75 Million through Underwritten Public Offering– Bolstered and Defended LIQ861 Patent Position– Advanced Efforts in Support of the RareGen, LLC Merger and Integration– Company to Host Webcast and Conference Call Today at 8:00 a.m. ETRESEARCH TRIANGLE PARK, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.“Despite the ongoing COVID-19 pandemic, we continue to make progress in defending our right to bring LIQ861 forward for patients, while also making significant strides to advance our mission through...

• Q3 Operating Income of $31.9 million and EBITDA plus stock-based compensation of $36.5 million• Year-to-date operating cash flow of $71.8 millionJOHNS CREEK, Ga., Nov. 09, 2020 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: EBIX), today announced the following results for the quarter ended September 30, 2020:Diluted EPS (GAAP) of $0.80 and Non-GAAP diluted EPS of $0.93Revenues of $154.3 million and constant currency revenues of $160.2 millionGAAP operating income of $31.9 million and Non-GAAP operating income of $35.8 millionEbix will host a conference call to review its results today at 11:00 a.m. EDT (details below).Ebix Chairman, President and CEO Robin Raina said, “In spite of the continued impact of COVID-19 across several major areas of our global operations, we are reporting Q3 2020 revenues of $154.3 million, a 39% increase over...

Positive topline results reported from Study ‘402, a Phase 3 Study evaluating lumateperone as an adjunctive treatment to lithium or valproate in patients with bipolar depression.Company is preparing sNDA for the treatment of bipolar depression for submission to the FDA. Study ‘402, in conjunction with our previously reported positive Phase 3 monotherapy study, Study 404, forms the basis for our sNDA.Strong CAPLYTA commercial performance with week-over-week and quarter-over-quarter prescription growth despite COVID-19 disruptions.Expanding lumateperone development in Major Depressive Disorder (MDD) and other depressive disorders and advancing a Long-Acting Injectable (LAI) formulation:A post-hoc analysis of Study ‘404, our global Phase 3 study in bipolar depression, demonstrated that lumateperone was effective in the subset of patients...

Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021Dosing in three new clinical trials with novel compounds incorporating PN chemistry and targeting SNP3 in HD, C9orf72 in ALS / FTD and exon 53 skipping in DMD expected in 2021Alpha-1 antitrypsin deficiency announced as first ADAR editing program, with potential to address both lung and liver manifestations of the disease through correction of single RNA base mutationStrengthened balance sheet with equity financing; cash runway extended into 2Q 2023Wave to host investor conference call and webcast at 8:30 a.m. ET todayCAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) —  Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...

– Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 –WEST CHESTER, Penn., Nov. 09, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2020.“We are encouraged by our recent Type A meeting with the FDA in which we discussed the steps required for resubmission of the NDA for VP-102, our lead product candidate, for the treatment of molluscum,” said Ted White, Verrica’s President and Chief Executive Officer. “We have also received feedback from the FDA on our Human Factors study protocol, and believe we have clear...

 – Off-road vehicles sales increased 51.6% to $8.9 million– Gross margin of 20.9% up versus 16.7% year-agoJINHUA, CHINA, Nov. 09, 2020 (GLOBE NEWSWIRE) — Kandi Technologies Group, Inc. (the “Company,” “we” or “Kandi”) (NASDAQ GS: KNDI), today announced its financial results for the third quarter of 2020.Operating HighlightsDuring the third quarter, Kandi achieved:In September, established China Battery Exchange Technology Company, a wholly-owned subsidiary for its battery swapping services.On August 18, Kandi America held a successful virtual launch event to introduce its K23 and K27 EVs into the U.S. market.In August, delivered its fully automatic intelligent battery exchange system to the rideshare operator in Haikou City, Hainan.In July, the Affiliate Company Fengsheng Automotive launched sales of the Maple 30X, its...